Sale!

ATXN3 Gene Spinocerebellar Ataxia Type 3 Autosomal Dominant Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The ATXN3 gene test for Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado-Joseph Disease, is a crucial diagnostic tool offered by DNA Labs UAE. This genetic test is aimed at detecting mutations in the ATXN3 gene, which are responsible for causing SCA3, a progressive neurodegenerative disorder. Characterized by a wide range of symptoms such as lack of coordination, difficulty with speech, and involuntary eye movements, SCA3 is inherited in an autosomal dominant manner, meaning that having just one copy of the altered gene can lead to the condition.

DNA Labs UAE provides this highly specialized test for a cost of 4400 AED. The test involves analyzing the patient’s DNA to identify the specific expansion of the CAG trinucleotide repeat in the ATXN3 gene that is indicative of SCA3. Early diagnosis through this genetic testing is crucial for management and treatment planning, as well as for providing genetic counseling to affected families, helping them understand the risk of transmission to future generations.

Description

ATXN3 Gene Spinocerebellar Ataxia Type 3 Autosomal Dominant Genetic Test

Test Name: ATXN3 Gene Spinocerebellar Ataxia Type 3 Autosomal Dominant Genetic Test

Components: Blood or Extracted DNA or One drop Blood on FTA Card

Price: 4400.0 AED

Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card

Report Delivery: 3 to 4 Weeks

Method: NGS Technology

Test Type: Neurological Disorders

Doctor: Neurologist

Test Department: Genetics

Pre Test Information: Clinical History of Patient who is going for ATXN3 Gene Spinocerebellar Ataxia Type 3, autosomal dominant NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with ATXN3 Gene Spinocerebellar Ataxia Type 3, autosomal dominant.

Test Details: The ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), which is an autosomal dominant genetic disorder. SCA3, also known as Machado-Joseph disease, is characterized by progressive degeneration of the cerebellum and other areas of the central nervous system. NGS (Next-Generation Sequencing) genetic testing is a method used to analyze the DNA sequence of a person’s genes. In the case of SCA3, NGS genetic testing can identify any mutations or variations in the ATXN3 gene that may be responsible for the development of the disorder. By identifying the specific genetic mutation causing SCA3, NGS genetic testing can provide a definitive diagnosis, help determine the prognosis, and inform treatment options for individuals and their families affected by this condition. Additionally, NGS testing can also be used for carrier screening, allowing individuals to determine their risk of passing on the mutated gene to their children. It is important to note that genetic testing for SCA3 should be performed by a qualified healthcare professional or genetic counselor who can provide appropriate counseling and guidance based on the results.

Test Name	ATXN3 Gene Spinocerebellar ataxia type 3 autosomal dominant Genetic Test
Components
Price	4400.0 AED
Sample Condition	Blood or Extracted DNA or One drop Blood on FTA Card o
Report Delivery	3 to 4 Weeks
Method	NGS Technology
Test type	Neurological Disorders
Doctor	Neurologist
Test Department:	Genetics
Pre Test Information	Clinical History of Patient who is going for ATXN3 Gene Spinocerebellar ataxia type 3, autosomal dominant NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with ATXN3 Gene Spinocerebellar ataxia type 3, autosomal dominant
Test Details	The ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), which is an autosomal dominant genetic disorder. SCA3, also known as Machado-Joseph disease, is characterized by progressive degeneration of the cerebellum and other areas of the central nervous system. NGS (Next-Generation Sequencing) genetic testing is a method used to analyze the DNA sequence of a person’s genes. In the case of SCA3, NGS genetic testing can identify any mutations or variations in the ATXN3 gene that may be responsible for the development of the disorder. By identifying the specific genetic mutation causing SCA3, NGS genetic testing can provide a definitive diagnosis, help determine the prognosis, and inform treatment options for individuals and their families affected by this condition. Additionally, NGS testing can also be used for carrier screening, allowing individuals to determine their risk of passing on the mutated gene to their children. It is important to note that genetic testing for SCA3 should be performed by a qualified healthcare professional or genetic counselor who can provide appropriate counseling and guidance based on the results.